Ascendia

  MARKET NEWS

Adragos Pharma Finalizes the Acquisition of Commercial-Scale, Sterile Fill-Finish Manufacturing Site From Sanofi
Cyclerion Therapeutics & Korsana Biosciences Announce Merger Agreement
Amprion Grows Global Footprint With Australian Partnership & Expanded Research Collaborations
Samsung Biologics Completes Acquisition of GSK’s Manufacturing Facility
PRISM ALS: New Stem Cell Models Could Transform Research Into Treatments for MND/ALS
Symeres & Ambagon Therapeutics Collaborate on Molecular Glue Research in Colorectal Cancer
ImmuneOncia Therapeutics & Lonza Collaborate to Manufacture a PD-L1 Antibody Targeting Immuno-Oncology
Thermo Fisher Scientific & SHL Medical Collaborate to Deliver Fully Integrated Drug-Device Solutions
Optibrium Introduces Graphical Interface for QuanSA to Enhance Ligand-Based Affinity Predictions
Quotient Therapeutics Announces Collaboration With Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology

  EXPERT CONTENT & RESOURCES

eBook: Understanding the Foundation of LNP Formulation Success

eBook: Understanding the Foundation of LNP Formulation Success

Lipid nanoparticles (LNPs) are one of the most significant advances in drug delivery in decades. But developing successful LNP formulations demands deep knowledge of their key building blocks: Lipids.

Portrait of Dr. Lara Zibners

The Most Underutilized Route in Drug Delivery: How Vaginal Therapeutics Are Finally Getting the Platform They Deserve

Before we dig into improved delivery methods, we need to acknowledge a more basic issue: women need more therapeutics in the first place. Persistent gaps exist across conditions that uniquely or disproportionally affect women. Gynecologic infections, endometriosis, the vaginal microbiome. Menopause, contraception, oncology.

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

Biocatalysis Without Barriers for Efficient Small Molecule Process Development

As the biocatalytic toolbox expands, chemists have gained access to a wider range of catalytic options, enabling improved stereo- and regioselectivity, simplified chemical synthesis routes, improved process mass intensity (PMI), reduced environmental impact and stronger process economics.

  FEATURED EDITORIAL

Drug Development & Delivery

  COMPANY PROFILE

Agno Pharmaceuticals is a leading, global, small molecule Contract Development and Manufacturing Organization (CDMO), catering to the specific needs of the branded pharmaceutical, biotech, generic, and CDMO sectors. Agno Pharmaceuticals is a US-based, end-to-end premier service provider. We specialize in supplying Registered Starting Materials (RSMs), custom Chemical Intermediates, Active Pharmaceutical Ingredients (APIs), highly potent APIs, sterile APIs, and complex Drug Product formulations (including long-acting injectables/implants) to our valued clientele worldwide. Our US-FDA inspected cGMP compliant manufacturing facilities ensures that we are able to provide our services at a level of unparalleled quality and compliance to our customer base. Click here for more.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

WHITEPAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development

Why Early Development Requires a Different Decision Model

Early oral drug development is an exercise in working under constraint. Teams are asked to make consequential decisions when materials are limited, timelines are tight, and the data are incomplete. Traditionally, formulation …

WHITEPAPER - Small Molecules: Choosing the Right Development Path

WHITEPAPER - Small Molecules: Choosing the Right Development Path

Summary

The white paper, Small Molecules: Choosing the Right Development Path, outlines a structured, risk-minimized approach to early CMC (Chemistry, Manufacturing, and Controls) development for small-molecule drugs—particularly for startups and virtual pharma companies with limited resources.

Key messages:

  • Start
…

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

WHITEPAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization

       
By:
Harry Wade, Technical Associate, and Rosie Bird, EHS Lead, Catalent Dartford

The pharmaceutical industry faces a growing manufacturing challenge as therapeutic compounds become increasingly potent and targeted. Oncology and hormonal APIs, often designed for ultra-low dosing, promise meaningful clinical …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 8 – Formulation Development
April 15 – Prefilled Syringes